SPR Therapeutics
http://www.sprtherapeutics.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From SPR Therapeutics
Adalvo Celebrates Unique European Nod For Prolonged-Release Pregabalin
Adalvo, the B2B unit of the Alvo group of companies, has announced a successful decentralized European approval for its pregabalin prolonged-release tablets, with a launch imminent. The “milestone” for its value added medicines program could allow the firm to offer what it has previously billed as “the first once-daily pregabalin formulation.”
Sandoz US CCO Calls For Authorized Generic Omission From IRA
The Inflation Reduction Act should take a different approach when it comes to authorized generic products, Sandoz US chief commercial officer Tim DeGavre has told Generics Bulletin.
Sandoz Eyes First-To-Market US Opportunities With Adalvo Deal
Sandoz has struck a deal with Adalvo that will give the company rights to six products in the US – four of which are potential first-to-market opportunities – targeting markets that are collectively worth around $3bn.
Multiple Agreements At Adalvo As Company Expects To File 30 DCPs This Year
Alvo group B2B unit Adalvo expects to file 30 decentralized procedures in Europe over the coming year as it expands its partnerships with Frontier Biopharma, Zentiva and Stada.
Company Information
- Industry
-
Medical Devices
- Implantable Devices
-
Surgical Equipment & Devices
- Minimally or Less Invasive
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice